How much does lapatinib cost to treat HER2-positive breast cancer?

Lapatinib, an oral small molecule targeted drug, has now become an important treatment for HER2 (human epidermal growth factor receptor 2)-positive breast cancer. Especially for those patients who have failed to respond to anthracyclines, taxanes, trastuzumab and other treatment regimens, or whose cancer has entered an advanced stage and has metastasized, lapatinib combined with capecitabine provides a new treatment strategy.

The core mechanism of this drug is that it can effectively inhibit the tyrosine kinase activity of the HER2 receptor, thereby blocking the signal transduction of HER2. This property allows lapatinib to precisely target HER2 overexpressed breast cancer cells, thereby achieving highly effective treatment.

In actual clinical application, doctors will tailor a combined treatment plan of lapatinib and chemotherapy drugs based on the patient's specific condition. This combined treatment approach has been shown to significantly extend the lives of patients withHER2positive breast cancer and significantly improve their quality of life.

Of course, any drug comes with certain side effects. Patients taking lapatinib may experience gastrointestinal discomfort, such as nausea, diarrhea and other symptoms, or skin reactions, such as dryness, rash, etc. Long-term use may also affect heart and liver function, so regular physical examinations are essential.

As for the price, the current price of lapatinib's original drug per bottle (70tablets250mgtablets) in domestic and foreign markets is approximately 6,000 yuan. But the good news is that generic drugs are already on the market in India and Bangladesh. The price of 30 tablets in overseas markets is between 600 and 900 yuan, which undoubtedly provides patients with more choices.

In general, lapatinib not only brings new treatment opportunities to HER2 positive breast cancer patients, but also brings hope of life to those patients who are resistant to traditional treatments.

xa0

Reference materials:https://www.mayoclinic.org/drugs-supplements/lapatinib-oral-route/description/drg-20070910